Metabolism - Clinical and Experimental
Volume 45, Issue 11 , Pages 1375-1382, November 1996

High-density lipoprotein: Relations to metabolic parameters and severity of coronary artery disease

  • Per Tornvall

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Per Tornvall, MD, King Gustaf V Research Institute, Karolinska Hospital, S-171 76 Stockholm, Sweden.
    • Atherosclerosis Research Unit, King Gustaf V Research Institute, Stockholm, Sweden
    • Atherosclerosis Research Unit, Karolinska Institute, Stockholm, Sweden
    • Departments of Cardiology, Internal Medicine, and Thoracic Radiology, Karolinska Hospital, Stockholm, Sweden
    • Department of Medical Biochemistry and Biophysics, University of Umeå, Umeå, Sweden
    • Wynn Department of Metabolic Medicine, the National Heart and Lung Institute, London, UK
  • ,
  • Fredrik Karpe

      Affiliations

    • Atherosclerosis Research Unit, King Gustaf V Research Institute, Stockholm, Sweden
    • Atherosclerosis Research Unit, Karolinska Institute, Stockholm, Sweden
    • Departments of Cardiology, Internal Medicine, and Thoracic Radiology, Karolinska Hospital, Stockholm, Sweden
    • Department of Medical Biochemistry and Biophysics, University of Umeå, Umeå, Sweden
    • Wynn Department of Metabolic Medicine, the National Heart and Lung Institute, London, UK
  • ,
  • Anthony Proudler

      Affiliations

    • Atherosclerosis Research Unit, King Gustaf V Research Institute, Stockholm, Sweden
    • Atherosclerosis Research Unit, Karolinska Institute, Stockholm, Sweden
    • Departments of Cardiology, Internal Medicine, and Thoracic Radiology, Karolinska Hospital, Stockholm, Sweden
    • Department of Medical Biochemistry and Biophysics, University of Umeå, Umeå, Sweden
    • Wynn Department of Metabolic Medicine, the National Heart and Lung Institute, London, UK
  • ,
  • Peter Båvenholm

      Affiliations

    • Atherosclerosis Research Unit, King Gustaf V Research Institute, Stockholm, Sweden
    • Atherosclerosis Research Unit, Karolinska Institute, Stockholm, Sweden
    • Departments of Cardiology, Internal Medicine, and Thoracic Radiology, Karolinska Hospital, Stockholm, Sweden
    • Department of Medical Biochemistry and Biophysics, University of Umeå, Umeå, Sweden
    • Wynn Department of Metabolic Medicine, the National Heart and Lung Institute, London, UK
  • ,
  • Christian Landou

      Affiliations

    • Atherosclerosis Research Unit, King Gustaf V Research Institute, Stockholm, Sweden
    • Atherosclerosis Research Unit, Karolinska Institute, Stockholm, Sweden
    • Departments of Cardiology, Internal Medicine, and Thoracic Radiology, Karolinska Hospital, Stockholm, Sweden
    • Department of Medical Biochemistry and Biophysics, University of Umeå, Umeå, Sweden
    • Wynn Department of Metabolic Medicine, the National Heart and Lung Institute, London, UK
  • ,
  • Thomas Olivecrona

      Affiliations

    • Atherosclerosis Research Unit, King Gustaf V Research Institute, Stockholm, Sweden
    • Atherosclerosis Research Unit, Karolinska Institute, Stockholm, Sweden
    • Departments of Cardiology, Internal Medicine, and Thoracic Radiology, Karolinska Hospital, Stockholm, Sweden
    • Department of Medical Biochemistry and Biophysics, University of Umeå, Umeå, Sweden
    • Wynn Department of Metabolic Medicine, the National Heart and Lung Institute, London, UK
  • ,
  • Anders Hamsten

      Affiliations

    • Atherosclerosis Research Unit, King Gustaf V Research Institute, Stockholm, Sweden
    • Atherosclerosis Research Unit, Karolinska Institute, Stockholm, Sweden
    • Departments of Cardiology, Internal Medicine, and Thoracic Radiology, Karolinska Hospital, Stockholm, Sweden
    • Department of Medical Biochemistry and Biophysics, University of Umeå, Umeå, Sweden
    • Wynn Department of Metabolic Medicine, the National Heart and Lung Institute, London, UK

Received 12 December 1995; accepted 21 May 1996.

Abstract 

The regulation of plasma high-density lipoprotein (HDL) cholesterol level by the joint influence of plasma lipoprotein lipids, lipoprotein lipase (LPL), hepatic lipase (HL), cholesteryl ester transfer protein (CETP), oral glucose tolerance, and postload plasma insulin and proinsulin levels was investigated in young postinfarction patients and healthy population—based control subjects. In addition, the association between HDL cholesterol and the number and severity of coronary stenoses previously reported in this cohort of young postinfarction patients was further investigated by analyzing the determinants and angiographic relations of HDL subclasses measured by gradient gel electrophoresis. The following parametres showed significant univariate relations with HDL choleterol level in the patient group: very—low-density lipoprotein (VLDL) cholesterol and triglyceride, low-density lipoprotein (LDL) triglyceride, and postload plasma insulin concentrations, preheparin plasma LPL mass, and postheparin plasma HL activity. In the control group, significant correlations with HDL cholesterol concentration in addition to those noted among the patients were found for body mass index (BMI), LDL cholesterol level postload plasma intact proinsulin concentration, and LPL activity in postheparin plasma. In contrast to the patients, no significant relations were noted for postload plasma insulin level and preheparin plasma LPL mass. Multiple stepwise regression analysis showed that 42% of the variability of HDL cholesterol in the patients could be accounted for by VLDL cholesterol concentration (29%), LDL triglyceride level (7%), and postheparin plasma HL activity (6%), whereas the corresponding figure in controls was 35% (VLDL cholesterol concentration [9%] and postheparin plasma HL activity [26%]). The strength of the relationships of HDL cholesterol and HDL subclasses to the coronary stenosis score was similar and statistically significant (r = .25 to .36). When the metabolic parameters that correlated with HDl cholesterol and HDL subclass concentrations in univariate analysis were used as covariates, all relations to the coronary stenosis score disappeared. This clearly indicates that the influence of triglyceride-rich lipoproteins and lipolytic enzymes needs to be considered when assessing the association between HDL cholesterol and coronary artery disease (CAD).

No full text is available. To read the body of this article, please view the PDF online.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by the Swedish Heart-Lung Foundation, the Swedish Medical Research Council (8691), the Marianne and Marcus Wallenberg Foundation, the Nordic Insulin Foundation, the King Gustaf V 80th Birthday Fund, and the Professor Nanna Svartz Fund.

PII: S0026-0495(96)90118-3

Metabolism - Clinical and Experimental
Volume 45, Issue 11 , Pages 1375-1382, November 1996